With the recent ODAC review of the commerically available CAR-T therapies in relapsed/refractory myeloma post 1-3 lines of therapy, what is your preferred regimen/therapy for first relapse, and which are the situations where you would absolutely consider CAR-T therapy at first relpase?

Answer from: Medical Oncologist at Academic Institution

So, in a twist that almost never happens in myeloma, I largely still agree with my answer from a year ago: https://www.themednet.org/question/16578 In brief, at that time, I'd suggested that CAR-T primarily be used from the third line onwards - i.e., after at least two prior lines have faile...

Comments

Medical Oncologist at Winship Cancer Institute of Emory University
Well said

Please select the option that best describes you:

With the recent ODAC review of the commerically available CAR-T therapies in relapsed/refractory myeloma post 1-3 lines of therapy, what is your preferred regimen/therapy for first relapse, and which are the situations where you would absolutely consider CAR-T therapy at first relpase?

Related Questions